Finance

Beta
Ask
Lists
002800:KOSDAQ
Sinsin Pharmaceutical Co Ltd
₩4,715.00
+3.97%
(+180.00) 1D
Jun 12, 11:52:50 AM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 002800...
Open
₩4,535
High
₩4,715
Low
₩4,535
Mkt. cap
71.60B
Avg. vol.
65.47K
Volume
23.90K
Dividend
1.70%
Quarterly dividend
₩20
Ex-dividend date
Dec 27, 2024
P/E ratio
6.41
52-wk high
₩6,990
52-wk low
₩4,295
EPS
₩735
Shares outstanding
15.17M
No. of employees
356
Open
₩4,535
High
₩4,715
Low
₩4,535
Mkt. cap
71.60B
Avg. vol.
65.47K
Volume
23.90K
Dividend
1.70%
Quarterly dividend
₩20
Ex-dividend date
Dec 27, 2024
P/E ratio
6.41
52-wk high
₩6,990
52-wk low
₩4,295
EPS
₩735
Shares outstanding
15.17M
No. of employees
356
News stories
From sources across the web
About Sinsin Pharmaceutical Co Ltd
CEOByoungKi Lee
Employees356
Founded1959
Headquarters-
SectorPharmaceutical industry
Websitesinsin.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
29.60B
30.11B
28.76B
30.18B
Cost of goods sold
18.47B
18.32B
17.51B
18.67B
Cost of revenue
18.47B
18.32B
17.51B
18.67B
Research and development expenses
44.92M
156.94M
275.88M
136.53M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.53B
7.36B
7.33B
7.76B
Operating expense
8.90B
7.83B
7.91B
8.33B
Total operating expenses
27.38B
26.16B
25.42B
27.00B
Operating income
2.22B
3.96B
3.34B
3.18B
Other non operating income
41.14M
14.65M
464.34M
23.56M
EBT including unusual items
1.48B
3.75B
3.65B
3.19B
EBT excluding unusual items
1.48B
3.74B
3.51B
3.19B
Income tax expense
90.83M
347.04M
154.08M
334.12M
Effective tax rate
6.12%
9.26%
4.22%
10.46%
Other operating expenses
76.65M
75.40M
62.30M
163.70M
Net income
1.37B
3.42B
3.50B
2.86B
Net profit margin
4.63%
11.36%
12.16%
9.49%
Earnings per share
-
-
-
-
Interest and investment income
5.70M
6.32M
11.16M
16.65M
Interest expense
-426.96M
-390.64M
-370.91M
-340.70M
Net interest expenses
-421.25M
-384.32M
-359.75M
-324.06M
Depreciation and amortization charges
252.68M
235.18M
230.39M
229.79M
EBITDA
3.25B
4.97B
4.34B
4.20B
Gain or loss from assets sale
-1.56M
-12.70M
-
-
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more